{{Rsnum
|rsid=3755557
|Gene=GSK3B
|Chromosome=3
|position=120096110
|Orientation=plus
|GMAF=0.1488
|Gene_s=GSK3B,LOC100996310
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 1.5 | 33.8 | 64.6
| HCB | 2.3 | 11.4 | 86.4
| JPT | 4.7 | 27.9 | 67.4
| YRI | 3.2 | 15.9 | 81.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 2.3 | 11.4 | 86.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20605420
|Title=Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians
}}

{{PMID Auto
|PMID=21996267
|Title=Genetic association and identification of a functional SNP at GSK3? for schizophrenia susceptibility
}}

{{PMID Auto
|PMID=17160944
|Title=[Correlation between gene polymorphisms of Wnt signalling pathway related components and risk of gastric carcinoma: a case-control study].
}}

{{PMID Auto
|PMID=18676680
|Title=Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.
|OA=1
}}

{{PMID Auto
|PMID=19252927
|Title=Bladder cancer SNP panel predicts susceptibility and survival.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}